CN103381182B - The application of Houttuynoid C in preparation treatment myocardial ischemia drug - Google Patents

The application of Houttuynoid C in preparation treatment myocardial ischemia drug Download PDF

Info

Publication number
CN103381182B
CN103381182B CN201310253924.8A CN201310253924A CN103381182B CN 103381182 B CN103381182 B CN 103381182B CN 201310253924 A CN201310253924 A CN 201310253924A CN 103381182 B CN103381182 B CN 103381182B
Authority
CN
China
Prior art keywords
myocardial ischemia
houttuynoid
application
preparation treatment
control group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201310253924.8A
Other languages
Chinese (zh)
Other versions
CN103381182A (en
Inventor
丁圣雨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dongtai Haibin Science And Technology Pioneer Park Management Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201310253924.8A priority Critical patent/CN103381182B/en
Publication of CN103381182A publication Critical patent/CN103381182A/en
Application granted granted Critical
Publication of CN103381182B publication Critical patent/CN103381182B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention provides the application of Houttuynoid C in preparation treatment or prevention myocardial ischemia drug.The Houttuynoid C that the present invention relates to belongs to first public preparing the purposes in medicaments for resisting myocardial ischemia, because framework types belongs to brand-new framework types, and its inhibit activities for myocardial ischemia is unexpectedly strong, there is not the possibility being provided any enlightenment by other compounds, possessing outstanding substantive distinguishing features, for resisting myocardial ischemia, obviously there is significant progress simultaneously.

Description

The application of Houttuynoid C in preparation treatment myocardial ischemia drug
Technical field
The present invention relates to the application of Houttuynoid C in preparation treatment or prevention myocardial ischemia drug.
Background technology
The present inventor is found by a large amount of experiments, and Houttuynoid C has the/pharmacological action of reperfusion injury that resists myocardial ischemia, and has the medical usage of prevention or treatment myocardial ischemia disease.
The compound H outtuynoid C that the present invention relates to is one and delivers (Chen in 2012, S.D.et al., 2012.Houttuynoid A-E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletonsfrom Houttuynia cordata.Organic Letters 14 (7), 1772 – 1775.) New skeleton compound, this compound has brand-new framework types, current purposes only relates to anti-herpes simplex virus activity (Chen, S.D.et al., 2012.Houttuynoid A-E, Anti-Herpes Simplex Virus Active Flavonoids withNovel Skeletons from Houttuynia cordata.Organic Letters 14 (7), 1772 – 1775.), the Houttuynoid C that the present invention relates to is belonged to first public preparing the purposes in medicaments for resisting myocardial ischemia, because framework types belongs to brand-new framework types, and its inhibit activities for myocardial ischemia is unexpectedly strong, there is not the possibility being provided any enlightenment by other compounds, possesses outstanding substantive distinguishing features, for resisting myocardial ischemia, obviously there is significant progress simultaneously.
Summary of the invention
The invention provides Houttuynoid C to prepare treatment or prevent the application in the medicine of Ischemic/reperfusion.
The present inventor demonstrates by the experiment in detailed description of the invention the effect that Houttuynoid C has treatment or prevention myocardial ischemia drug disease.
Described compound H outtuynoid C-structure is as shown in formula I:
The Houttuynoid C that the present invention relates to belongs to first public preparing the purposes in medicaments for resisting myocardial ischemia, because framework types belongs to brand-new framework types, and its inhibit activities for myocardial ischemia is unexpectedly strong, there is not the possibility being provided any enlightenment by other compounds, possessing outstanding substantive distinguishing features, for resisting myocardial ischemia, obviously there is significant progress simultaneously.
Detailed description of the invention
The preparation method of compound H outtuynoid C involved in the present invention is see document (Chen, S.D.et al., 2012.Houttuynoid A-E, Anti-Herpes Simplex Virus Active Flavonoids with NovelSkeletons from Houttuynia cordata.Organic Letters 14 (7), 1772 – 1775.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by any restriction of specific embodiment, but be limited by claim.
Embodiment 1: the preparation of compound H outtuynoid C tablet involved in the present invention:
Get 20 g of compound Houttuynoid C, add the customary adjuvant 180 grams preparing tablet, mixing, conventional tablet presses makes 1000.
Embodiment 2: the preparation of compound H outtuynoid C capsule involved in the present invention:
Get 20 g of compound Houttuynoid C, add prepare capsule customary adjuvant as starch 180 grams, mixing, encapsulatedly makes 1000.
Its pharmaceutically active is further illustrated below by pharmacodynamic experiment.
Experimental example: Houttuynoid C is on the impact of myocardial ischemia/reperfusion injury in rats
(1) experiment material: SD rat, male and female dual-purpose, body weight 190 ~ 210g.
(2) method and result
1) experimental technique
The acute myocardial ischemia experiment of pituitrin induction: rat is divided into 5 groups at random: positive drug control group, model control group, administration group 3 groups, often organizes 8.Administration group gastric infusion, positive drug control group and model control group give the distilled water gavage of consubstantiality accumulated amount every day, the continuous gavage 7d of each group.All after the 7th day gavage, 1.5 ~ 2.0h lumbar injection pentobarbital sodium 30mg/kg anaesthetizes, and adopts MS2302 multimedia biological signal collecting analytical system to continue record standard II lead electrocardiogram.The Electrocardiographic change of record 15min continuously after positive drug control group, model control group and administration group sublingual vein injection of pituitrin 5IU/kg (complete in 5s, positive drug control group is 10min lumbar injection nitroglycerin 5mg/kg before injection of pituitrin) 10min.If there is one of following change in electrocardiogram: T ripple is low flat, two-way, and be inverted, ST section level moves down >=0.05mV, gives note 1 point.Finally analyze the total score of every rat, as reduced after medication score, prompting myocardial ischemia is improved.The impact of medicine on heart rate is represented with changes in heart rate percentage rate before and after injection of pituitrin.
Cardiac muscle ischemia resisting reperfusion injury experiment: rat is divided into 5 groups at random: positive drug control group, model control group, administration group 3 groups, often organizes 8.Administration group gastric infusion, positive drug control group and model control group give the distilled water gavage of consubstantiality accumulated amount every day, the continuous gavage 7d of each group.Record standard II lead electrocardiogram after rats by intraperitoneal injection pentobarbital sodium 30mg/kg anaesthetizes.Tracheal intubation, meets artificial respirator (1.0mlg -1min -1), thoracic cavity is opened at 4th ~ 5 intercostals, expose heart, at pulmonary conus left border, left auricle lower edge 1mm place is with 320 silk thread ligation ramus descendens anterior arteriae coronariae sinistraes (positive drug control group 3min sublingual vein before following coronary artery occlusion injects Propranolol 1.0mg/kg).After ligation 30min, cut off ligature, fill with 30min again.Quick taking-up heart, rinses well with 0.9% sodium chloride.Myocardium sheet is placed in the TTC solution of 1%, in 37 DEG C of hatching 5min.Rinse with water immediately after dyeing and remove dyestuff unnecessary on myocardium sheet.Cut off the non-infarcted region cardiac muscle that each myocardium sheet is colored, undyed infarcted myocardium and ischemic myocardium are weighed.
Hemodynamics is tested: rat is divided into 5 groups at random: positive drug control group, model control group, administration group 3 groups, often organizes 8.Administration group gastric infusion, positive drug control group and model control group give the distilled water gavage of consubstantiality accumulated amount every day, the continuous gavage 5d of each group.Within 6th day, lumbar injection urethane 10mg/kg anaesthetizes.Record standard II lead electrocardiogram.Longitudinally cut right skin of neck, be separated right common carotid artery, insert the left ventricular catheter being full of heparin 0.9% sodium chloride, conduit is slowly inserted left ventricular cavity.Cut left lower extremity inside skin, be separated femoral artery, insert ductus arteriosus.Cut-in pressure transducer, transports to multimedia bio signal monitor signal and observes.After balance 30min, each hemodynamic index before record administration.
So data all represent with x ± s, experimental group and the matched group data analysis sided t of two sample averages are checked.
2) result
Ischemia/reperfusion injury experimental result shows, under administration group, positive drug control group, model control group myocardial infarction and ligature, myocardial Mass Measured percentage ratio is respectively in table 1.
Table 1 Houttuynoid C is on the impact of scheming weight ratio under myocardial infarction and ligature
Compare with model comparison, * * p<0.01, * p<0.05
Houttuynoid C on the impact of the acute myocardial ischemia that pituitrin causes in table 2.
Table 2 Houttuynoid C is on the impact of the acute myocardial ischemia that pituitrin causes
Compare with model comparison, * * p<0.01, * p<0.05
Conclusion: Houttuynoid CA can reduce the generation of myocardial infarction, Houttuynoid C obviously can change the change of electrocardio degree, does not change heart rate.More than experiment can illustrate, Houttuynoid C can prevention and therapy myocardial ischemia.

Claims (1)

1.Houttuynoid C preparation treatment or prevention myocardial ischemia drug in application, described compound H outtuynoid C-structure as formula Ishown in:
formula I.
CN201310253924.8A 2013-06-24 2013-06-24 The application of Houttuynoid C in preparation treatment myocardial ischemia drug Active CN103381182B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310253924.8A CN103381182B (en) 2013-06-24 2013-06-24 The application of Houttuynoid C in preparation treatment myocardial ischemia drug

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310253924.8A CN103381182B (en) 2013-06-24 2013-06-24 The application of Houttuynoid C in preparation treatment myocardial ischemia drug

Publications (2)

Publication Number Publication Date
CN103381182A CN103381182A (en) 2013-11-06
CN103381182B true CN103381182B (en) 2015-09-16

Family

ID=49489249

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201310253924.8A Active CN103381182B (en) 2013-06-24 2013-06-24 The application of Houttuynoid C in preparation treatment myocardial ischemia drug

Country Status (1)

Country Link
CN (1) CN103381182B (en)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Chen,S.D.et al..Houttuynoid A-E,Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata.《Organic Letters》.2012,第14卷(第7期),第1772–1775页. *

Also Published As

Publication number Publication date
CN103381182A (en) 2013-11-06

Similar Documents

Publication Publication Date Title
CN103638012B (en) Application of Myrtucommuacetalone in medicine for treatment of myocardial ischemia
CN108245502A (en) Purposes of the rheum emodin succinyl ester type compound in medicaments for resisting myocardial ischemia is prepared
CN102423308A (en) Two bromophenol compounds and application of pharmaceutically-acceptable salts of two bromophenol compounds in preparation of protection drug
CN103768051B (en) The application of Eryngiolide A in preparation treatment myocardial ischemia drug
CN103381182B (en) The application of Houttuynoid C in preparation treatment myocardial ischemia drug
CN103520170B (en) Kadcoccitones A application in preparation treatment myocardial ischemia drug
CN103393703B (en) The application of Houttuynoid B in preparation treatment myocardial ischemia drug
CN103356681B (en) The application of Houttuynoid A in preparation treatment myocardial ischemia drug
CN103356647B (en) The application of Chukrasone A in preparation treatment myocardial ischemia drug
CN103356595B (en) The application of Chukrasone B in preparation treatment myocardial ischemia drug
CN105412073A (en) Application of Spirooliganone B in preparation of myocardial ischemia treatment drug
CN103751182B (en) The application of a kind of compound in treatment myocardial ischemia drug
CN103479609A (en) Application of Scopariusins in preparation of myocardial ischemia treatment medicines
CN105412068A (en) Application of Rearranged abietane diterpenoid in preparation of drugs for treating myocardial ischemia
CN105250269A (en) Application of Nagelamides X in preparation of drug for treating myocardial ischemia
CN105380940A (en) Use of Rhodomicranols B in preparation of drug for treating myocardial ischemia
CN102988351A (en) Application of Aphanamixoid A for preparing medicine for treating myocardial ischemia
CN102861035B (en) Application of Gypensapogenin B in medicine for treating myocardial ischemia
CN105168207A (en) Medicine for treating myocardial ischemia and application thereof
CN106344579A (en) Application of Fistulains A in drugs for myocardial ischemia treatment
CN103381178A (en) Application of Houttuynoid D in drug for treatment of myocardial ischemia
CN103356676A (en) Application of Houttuynoid E in medicine for treating myocardial ischemia
CN103340886A (en) Application of Polyflavanostilbene A in preparation of medicine for treating myocardial ischemia
CN103479620A (en) Application of Neonectrolide A to in preparation of medicament for treating myocardial ischemia
CN103610678B (en) The application of Trigolutesins A in treatment myocardial ischemia drug

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20171106

Address after: 401120 Chongqing Yubei District Food City Avenue 18 Chongqing advertising industrial park office space

Patentee after: Chongqing San Mou science and Technology Development Co., Ltd.

Address before: 210009 Gulou District, Jiangsu, Nanjing Gu Ping Kong, No. 4

Patentee before: Ding Shengyu

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20201223

Address after: 224200 No.88 Gangcheng Avenue, Dongtai coastal economic zone, Yancheng City, Jiangsu Province

Patentee after: Dongtai Haibin science and Technology Pioneer Park Management Co., Ltd

Address before: 401120 office building of Chongqing advertising industrial park, No.18, shifucheng Avenue, Yubei District, Chongqing

Patentee before: CHONGQING SUMARTE TECHNOLOGY DEVELOPMENT Co.,Ltd.